A subsidiary of pharmaceutical giant Johnson & Johnson (J&J) has pleaded guilty in federal court to misdemeanor charges of marketing a drug for unapproved uses. The guilty plea comes as part of a larger, $81-million settlement signed by J&J to settle government allegations that it illegally marketed its anti-seizure drug Topamax for the treatment of conditions including bipolar disorder and drug and alcohol addiction.
With a seemingly altruistic agenda, the fact is the campaign to end the “stigma” of mental illness is one driven and funded by pharma, psychiatry and pharmaceutical front groups such as NAMI and CHADD to name but a few. For example, take NAMI’s campaign to stop the “stigma” and “end discrimination” against the mentally ill—the “Founding Sponsors” were Abbott Labs, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer, Novartis, SmithKline Beecham and Wyeth-Ayerst Labs.
Do you question authority? Fail to accept conventional wisdom? Lose your temper when you hear a politician make a promise that you know he or she can’t keep?
If so, you may be mentally ill, according to the most recent revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM). In this revision, psychiatrists hope to add dozens of new mental disorders. Unfortunately, many of these so-called illnesses target people who merely think or behave differently from the majority population.
Forest Labs (FRX) appears to have initially underestimated how much it needed to pay the feds to go away: In 2009, the company said it had set aside $170 million in case it needed to settle a Department of Justice investigation of the kickbacks it paid in its marketing of Celexa and Lexapro, two antidepressants. Today, the company paid $313 million to wrap up the probes. Forest’s management is used to lavish spending, however, as the whistleblower complaints behind the settlement allege. The meat of Forest’s wrongdoing is that the company promoted Celexa for children even though the FDA had specifically rejected the drug for kids, and even though European data showed it was not useful in youths. The company did something similar with Lexapro — one pharmaceutical sales rep recommended crushing up Lexapro into apple sauce in order to make it more palatable to children.
Russell Williams, president of Canada’s Pharmaceutical Companies, recently wrote an opinion piece criticizing a series of articles that I wrote on antidepressants. His article was headlined: “Drug industry ethical standards high.”
Curiously, Williams did not address my concern that a review from the United States Food and Drug Administration found that antidepressants not only have no benefit in children, but are associated with a 50 per cent increase in suicidal behaviour.
SHARE YOUR STORY/COMMENT: